S&P rates Actavis loan BBB-

Standard & Poor's said it assigned a BBB- rating to Actavis Capital Sarl's proposed $1.75 billion term loan, which is guaranteed by its parent Actavis plc.

The corporate credit rating on Actavis is BBB- and the outlook is stable.

The ratings reflect the company's satisfactory business risk profile and significant financial risk profile, S&P said.

The ratings also consider the company's well-established position as one of the largest companies in the competitive generic drug industry and its growing portfolio of specialty branded products, the agency said.

The pending acquisition of Forest Laboratories will add to the company's higher margin specialty pharmaceutical portfolio, S&P said.

The company's patent-protected specialty pharmaceutical franchise somewhat insulates the company from the intense price competition in the generic drug segment, the agency added.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.